Challenges to this gene therapy modality include the need to remove only one copy of the PMP22 gene without disrupting the second copy, and also the efficiencies of infection and genome editing in adult Schwann cells, which produce the myelin sheath of peripheral nerves. Here, PMP22 is linked to infection.